Members of The Meters, moe., The Disco Biscuits, Dead & Company, and more joined forces in New Orleans for a heartfelt tribute to Phil Lesh.

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Cardiff Oncology has sufficient funds to operate until early 2027 but will face funding challenges by 2026. Learn why CRDF ...

Preliminary results from the AACR 2025 Annual Meeting reveal encouraging clinical responses to the investigational oral agent ...

Edible Garden expands its hydroponic herb line to 93 Stop & Shop stores in New York, boosting access to locally grown, sustainable produce.

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

HonorHealth Research Institute's new downtown Phoenix laboratory has produced its first study, centered on a promising new ...

Co. Ltd. showed positive results for its lead candidate, next-generation KRAS G12C inhibitor, D3S-001, also known as elisrasib, in patients with KRAS G12C mutation cancers, including patients ...

Markets regulator Sebi on Tuesday issued a draft framework on the structured exit process for KYC registration agencies and ...

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...

Johanna Joyce, PhD, then took the rostrum and spoke eloquently on the tumor microenvironment, underscoring the immense ...